Disease diversity and FLT3 mutations

被引：5
|
作者：
Smith, Catherine Choy [1 ]
机构：
[1] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA 94143 USA
来源：
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA | 2013年 / 110卷 / 52期
关键词：
ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; GASTROINTESTINAL STROMAL TUMORS; KINASE DOMAIN MUTATIONS; THERAPEUTIC TARGET; ITD MUTATIONS; RESISTANCE; VALIDATION; ACTIVATION; GEFITINIB;
D O I：
10.1073/pnas.1320579110
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
引用
收藏
页码：20860 / 20861
页数：2
相关论文
共 50 条
  • [11] Mutation Spectrum of FLT3 and Significance of Non-Canonical FLT3 Mutations in Hematological Malignancies
    Ge, Shuai-Shuai
    Shen, Xiangdong
    Wu, Tianmei
    Du, Jiahui
    Dai, Haiping
    Qiu, Qiaocheng
    Liu, Songbai
    Wu, Depei
    Xue, Shengli
    BLOOD, 2022, 140 : 1425 - 1426
  • [12] AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations
    Choudhary, C
    Schwäble, J
    Brandts, C
    Tickenbrock, L
    Sargin, B
    Kindler, T
    Fischer, T
    Berdel, WE
    Müller-Tidow, C
    Serve, H
    BLOOD, 2005, 106 (01) : 265 - 273
  • [13] Mutations in FLT3/ITD Produce Varying Levels of Resistance to FLT3 Tyrosine Kinase Inhibitors.
    Williams, Allen
    Nguyen, Bao
    Levis, Mark
    Brown, Patrick
    Small, Donald
    BLOOD, 2009, 114 (22) : 1452 - 1453
  • [14] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
    C C Smith
    K Lin
    A Stecula
    A Sali
    N P Shah
    Leukemia, 2015, 29 : 2390 - 2392
  • [15] Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
    Dzama, Margarita M.
    Steiner, Marlene
    Rausch, Johanna
    Sasca, Daniel
    Schoenfeld, Jonas
    Kunz, Kerstin
    Taubert, Martha C.
    McGeehan, Gerard M.
    Chen, Chun-Wei
    Mupo, Annalisa
    Haehnel, Patricia
    Theobald, Matthias
    Kindler, Thomas
    Koche, Richard P.
    Vassiliou, George S.
    Armstrong, Scott A.
    Kuehn, Michael W. M.
    BLOOD, 2020, 136 (21) : 2442 - 2456
  • [16] Therapeutic targeting of FLT3 mutations in AML via menin-MLL1 and FLT3 inhibition
    Dzama, Margarita M.
    Taubert, Martha C.
    Kunz, Kerstin
    Rausch, Johanna
    Chen, Chun-Wei
    Mupo, Annalisa
    Theobald, Matthias
    Kindler, Thomas
    Koche, Richard P.
    Vassiliou, George S.
    Armstrong, Scott A.
    Kuehn, Michael W.
    CANCER RESEARCH, 2019, 79 (13)
  • [17] Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics
    Magalhaes, Eduardo Sabino
    Hubner, Stefan
    Brown, Brandon D.
    Qiu, Yihua
    Kornblau, Steven M.
    BLOOD, 2023, 142
  • [18] Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations
    Tarver, Theodore C.
    Hill, Jason E.
    Rahmat, Leena
    Perl, Alexander E.
    Bahceci, Erkut
    Mori, Kenichi
    Smith, Catherine C.
    BLOOD ADVANCES, 2020, 4 (03) : 514 - 524
  • [19] FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors
    Smith, C. C.
    Lin, K.
    Stecula, A.
    Sali, A.
    Shah, N. P.
    LEUKEMIA, 2015, 29 (12) : 2390 - 2392
  • [20] Distinct profile of FLT3 mutations in Brazil.
    Souza, DLCF
    Lima, ASG
    Santos, GAA
    Melato, LC
    Dore, AI
    Silva, DE
    Ismael, S
    Silva, WA
    Rego, EM
    BLOOD, 2005, 106 (11) : 211B - 212B
12345